Comments
Britain will be the first country to run final stage trials of an experimental coronavirus vaccine being developed by the pharmaceutical company Janssen, a subsidiary of Johnson & Johnson.
Scientists will begin recruiting some 6,000 people across the U.K. on Monday for the 12-month trial.
Dr. Saul Faust, who is helping lead the study, said the research will start first in Britain but aims to recruit a total of 30,000 people in six countries around the world.
The shot uses a harmless cold virus to deliver the spike protein of the coronavirus into the body, which scientists hope will prompt an immune response.
Faust said the news from Pfizer and its German partner BioNTech last week that their vaccine appears to be 90 per cent effective according to preliminary data was a welcome boost for their research.
Related Stories
Researchers identify more features of virus causing Covid-19 using primate model
It’s fantastic news that vaccines aimed at the spike protein can prevent coronavirus disease, Faust, a professor of pediatric immunology and infectious diseases at the University of Southampton, said at a news briefing.
We don’t know how each of these vaccines is going to behave and which are going to generate the better short and long-term immunity, he added.
Related Stories
Pfizer vaccine left several volunteers with “severe hangover”, headache: Report
Pfizer had employed over 43,000 volunteers from six countries to test their vaccine for the treatment of Covid-19Faust said half of the people in the new U.K. study will be given a placebo vaccine of saline.
He added that researchers are hoping to recruit people from groups disproportionately affected by Covid-19, including older people and those of ethnic minorities.
The Jannsen vaccine is among the six experimental coronavirus vaccines that Britain has ordered as part of a planned 350 million-dose stockpile.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.